Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor-derived p53 mutants induce NF-kappaB2 gene expression.

Mariano J Scian1, Katherine E R Stagliano, Michelle A E Anderson

  • 1Department of Biochemistry and Massey Cancer Center, Virginia Commonwealth University, P.O. Box 980614, Richmond, Virginia 23298, USA.

Molecular and Cellular Biology
|November 2, 2005
PubMed
Summary

Mutant p53 overexpression in cancer cells confers a survival advantage against chemotherapy. This involves the NF-kappaB2 pathway, offering a potential target for overcoming drug resistance in tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating multiplexing into confineable gene drives effectively overrides resistance in Anopheles stephensi.

Nature communications·2026
Same author

Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study.

Cancer·2026
Same author

Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage.

Cell death and differentiation·2026
Same author

Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology.

The Journal of clinical investigation·2025
Same author

Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage.

Research square·2025
Same author

Harnessing the highly adaptable barnase-barstar system for genetic biocontrol of Aedes aegypti.

Communications biology·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Overexpression of mutant p53 is prevalent in tumors, indicating its role in cancer progression.
  • Understanding the mechanisms by which mutant p53 confers a survival advantage is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate how mutant p53 expression impacts the survival of human cancer cells.
  • To identify specific molecular pathways involved in mutant p53-mediated chemoresistance.

Main Methods:

  • Generation of stable p53-null human lung carcinoma cell lines expressing specific p53 mutants (p53-R175H, -R273H, -D281G).
  • Assessment of cell survival following treatment with etoposide, a chemotherapeutic agent.
  • Gene expression profiling to identify genes upregulated by mutant p53.

Related Experiment Videos

  • Investigating the role of NF-kappaB2 using small interfering RNA and pathway activation analysis.

    • Main Results:

    • Mutant p53-expressing cells exhibited increased survival when treated with etoposide.
    • A transactivation-deficient mutant (p53-D281G) showed significantly lower resistance to etoposide.
    • Mutant p53 proteins induced the expression of approximately 100 genes related to cell growth, survival, and adhesion, including NF-kappaB2.
    • Overexpression of NF-kappaB2 alone conferred chemoresistance, and its inhibition sensitized cells to etoposide.
    • Activation of the NF-kappaB2 pathway was observed in mutant p53-expressing cells.

    Conclusions:

    • Mutant p53 can confer a survival advantage to cancer cells, contributing to chemoresistance.
    • The NF-kappaB2 pathway is implicated in mediating this drug resistance.
    • Targeting the NF-kappaB2 pathway may represent a therapeutic strategy to overcome mutant p53-driven chemoresistance.